Back to home » Top Stories » IAC 2010
XVIII International AIDS Conference
IAC 2010 XVIII International AIDS Conference
Reed Messe Wien
Vienna, Austria
July 18-23, 2010


Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment

July 19, 2010

By Tim Horn

A nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen consisting of Kaletra (lopinavir and ritonavir) plus Isentress (raltegravir) is comparable with a standard regimen consisting of Kaletra plus Truvada (tenofovir and emtricitabine) in people living with HIV starting antiretroviral (ARV) therapy for the first time, according to 48-week study results reported Monday, July 19, at the XVIII International AIDS Conference in Vienna.

Standard regimens for treatment-naive people living with HIV usually consist of two NRTIs plus either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI). Though such pairings are preferred, based on long-term safety and efficacy data reviewed by the U.S. Department of Health and Human Services in its HIV treatment guidelines, there has been an interest in using NRTI-sparing regimens, notably for those who experience side effects while using approved options or are believed to be at a high risk for NRTI-related toxicities (such as kidney damage).

Early data from the 96-week PROGRESS study, reported by Jacques Reynes, MD, of the University Hospital Center of Montpellier, France, and his colleagues, illustrate the potential of one such NRTI-sparing regimen. The open-label study—meaning everyone knows which drugs they are taking—has enrolled 101 patients to receive Kaletra plus twice-daily Isentress and 105 patients to receive Kaletra plus Truvada. The primary endpoint of the study is the percentage of patients with viral loads below 40 copies—undetectable—after 48 weeks of treatment.

Viral loads averaged 18,000 copies upon entering the study; CD4 counts averaged 293.5 cells. Approximately 85 percent of the study participants were men and approximately 75 percent were white.

A similar proportion of study volunteers in each arm discontinued treatment prematurely during the initial 48-week follow-up period: 12 percent in the Kaletra/Isentress group and 11 percent in the Kaletra/Truvada group. 

A similar proportion of patients had undetectable viral loads when treated with Kaletra/Isentress, compared with Kaletra/Truvada. About 83 percent had viral loads below 40 copies in the Kaletra/Isentress group, Reynes reported, compared with 85 percent in the Kaletra/Truvada group.

The average CD4 increases through 48 weeks were also similar. There was a 215-CD4 cell increase in the Kaletra/Isentress group, compared with a 245-CD4 cell increase in the Kaletra/Truvada group. This difference was not statistically significant, meaning that it could have been a result of chance. 

The authors also noted that no new protease mutations associated with Kaletra resistance developed in the study in either treatment group. An Isentress-associated resistance mutation was observed in one patients receiving Kaletra/Isentress, whereas an emtricitabine-associated resistance mutation was observed in one patients receiving Kaletra/Truvada.

Moderate-to-severe drug-related adverse effects were similar in both groups. The most common side effect was diarrhea, occurring in 8 percent of those receiving Kaletra/Isentress versus 13 percent of those receiving Kaletra/Truvada—this difference was not statistically significant. Lipid elevations—notably average increases in cholesterol and triglyceride levels—were observed more frequently in the Kaletra/Isentress group. Elevations in creatine phosphokinase levels were also more likely to occur among those receiving Kaletra/Isentress.

“The 48-week PROGRESS study results, while not definitive, suggest that the nucleoside-sparing HIV regimen of Kaletra and Isentress may be an alternative treatment option for patients new to HIV therapy, when compared to a standard HIV regimen,” Reynes concluded. “This further advances our research into new HIV treatment classes and explores the use of alternative drug combinations for patients.”

Search: Kaletra, lopinavir, ritonavir, Isentress, raltegravir, Truvada, tenofovir, emtricitabine, PROGRESS, Vienna, International AIDS Conference, Reynes

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

More from AIDS2010

HIV/AIDS Complications

July 28, 2010
Global Survey: Stigma, Isolation and Discrimination Still Pervasive
Universal HIV Treatment Access No Guarantee of Health for Socially Disadvantaged
July 27, 2010
OM-85 BV: A Bacterial Vaccine Against Respiratory Problems in People with HIV and COPD?
Low Vitamin D Levels Not Associated With HIV Drugs
July 23, 2010
Longer Duration of HIV Infection Might Increase the Risk of Brain Disorders
Nearly 75 Percent of People With HIV Might Have Bone Problems
July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 21, 2010
Non-AIDS Cancers Occurring at Earlier Age Among People With HIV
Hep C Treatment Effective in HIV Patients With Normal Liver Enzymes
Aging Might Have a Smaller Impact on Immune Function Than Suspected
July 20, 2010
Viramune Boosts Hep C Treatment Efficacy in People With HIV
HIV/HCV Coinfection Further Increases Risk of Bone Fractures
Fewer Malignancies Seen in Those Taking Selzentry

Experimental HIV Drugs

July 23, 2010
More Details of TBR-652’s Antiviral and Anti-Inflammatory Potential Reported
July 22, 2010
ViiV HIV Integrase Inhibitor Performing Well in First-Time Treatment Study
Rilpivirine Has Similar Efficacy and Better Tolerability Than Sustiva
Extended-Release Viramune Has Comparable Safety and Efficacy to Standard Viramune
July 20, 2010
New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains
July 19, 2010
Argos’s Dendritic Cell Therapy Reduces HIV During Treatment Interruption

HIV Transmission and Prevention

July 29, 2010
Prevention Is Failing to Target MSM When They’re Young Enough
July 26, 2010
HPV Cancer Vaccine Effective for Heterosexual, Gay and Bisexual Men
Study Finds PrEP Is Safe in Gay and Bi Men
July 23, 2010
Circumcision Unlikely to Have Major HIV Prevention Benefit Among Gay Men
July 21, 2010
Microbicide Success Story: What It Means and Where We Go Next
MACS: Childhood Sex Abuse and Victimization Linked to Increased HIV Risk
Full-Scale HIV Treatment and Prevention Could Save Millions of Lives
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
HIV Cases in Young People Are Falling Around the World
July 19, 2010
Preliminary Results Suggest Good Safety and Adherence Profile for PrEP

Starting and Switching Treatment

July 22, 2010
Reyataz/Isentress Combo Spares Norvir and Nukes, But Is Integrase Resistance a Concern?
Possibly No Survival Benefit to Starting HIV Treatment at CD4s of 500 or More
Once-Daily Prezista/Norvir Monotherapy Largely Effective Over 96 Weeks
Abacavir/Lamivudine Equivalent to Tenofovir/Emtricitabine in Canadian Cohort Study
July 19, 2010
Strategies for a Cure Reviewed in Vienna
Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment
Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects
Protease Inhibitor-to-Isentress Switch is Effective, Lipid Friendly


July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
5.2 Million People With HIV in Low- and Middle-Income Countries Now on Treatment
At Least 31 Countries Deporting People Living With HIV
HIV Cases in Young People Are Falling Around the World

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.